Cargando…

Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan

BACKGROUND: Human papillomavirus (HPV) infection has been shown to be a major risk factor for cervical cancer. Vaccines against HPV-16 and HPV-18 are highly effective in preventing type-specific HPV infections and related cervical lesions. There is, however, limited data available describing the hea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Pang-Hsiang, Hu, Fu-Chang, Lee, Ping-Ing, Chow, Song-Nan, Huang, Chao-Wan, Wang, Jung-Der
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822833/ https://www.ncbi.nlm.nih.gov/pubmed/20064239 http://dx.doi.org/10.1186/1472-6963-10-11

Ejemplares similares

Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan
por: Tang, Chao-Hsiun, et al.
Publicado: (2019)

Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China
por: Liu, Yi-Jun, et al.
Publicado: (2016)

Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers
por: Nayereh, Khadem Ghaebi, et al.
Publicado: (2012)

A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines
por: Guerrero, Anna Melissa, et al.
Publicado: (2015)

Pandemic (H1N1) 2009 Vaccination and Class Suspensions after Outbreaks, Taipei City, Taiwan
por: Hsueh, Po-Ren, et al.
Publicado: (2010)

Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis
por: Jiang, Y, et al.
Publicado: (2019)

Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study
por: Van Minh, Hoang, et al.
Publicado: (2017)

Cervical cancer prevention: An Italian scenario between organised screening and human papillomaviruses vaccination
por: Cappelli, Maria G., et al.
Publicado: (2018)

Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis
por: Kulasingam, Shalini L, et al.
Publicado: (2009)

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
por: Vokó, Zoltán, et al.
Publicado: (2012)

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
por: Westra, Tjalke A, et al.
Publicado: (2013)

Cost-effectiveness of human papillomavirus vaccination in Germany
por: Damm, Oliver, et al.
Publicado: (2017)

Costs of delivering human papillomavirus vaccination in Tanzania
por: Struckmann, V, et al.
Publicado: (2022)

Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan
por: Liu, Pang-Hsiang, et al.
Publicado: (2008)

Knowledge of Cervical Cancer and Acceptability of Prevention Strategies Among Human Papillomavirus-Vaccinated and Human Papillomavirus-Unvaccinated Adolescent Women in Eldoret, Kenya
por: Mburu, Anisa, et al.
Publicado: (2019)

Identifying Perceived Barriers to Human Papillomavirus Vaccination as a Preventative Strategy for Cervical Cancer in Nigeria
por: Nguyen, Nicole Yvonne, et al.
Publicado: (2020)

Therapeutic Vaccines Against Human Papillomavirus and Cervical Cancer
por: Cid-Arregui, Angel
Publicado: (2009)

Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China
por: Zou, Maosheng, et al.
Publicado: (2023)

Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion
por: Ravilla, Rahul, et al.
Publicado: (2019)

Trend and survival outcome in Taiwan cervical cancer patients: A population-based study
por: Kau, Yi-Chuan, et al.
Publicado: (2019)

Cost-effectiveness of Human Papillomavirus Vaccination in the United States
por: Chesson, Harrell W., et al.
Publicado: (2008)

Cost Effectiveness of a Potential Vaccine for Human papillomavirus
por: Sanders, Gillian D., et al.
Publicado: (2003)

Cost-effectiveness of different human papillomavirus vaccines in Singapore
por: Lee, Vernon J, et al.
Publicado: (2011)

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
por: Kosen, Soewarta, et al.
Publicado: (2017)

Cost of a human papillomavirus vaccination project, Zimbabwe
por: Hidle, Anna, et al.
Publicado: (2018)

Valuation of the EQ-5D-5L in Taiwan
por: Lin, Hsiang-Wen, et al.
Publicado: (2018)

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors
por: Damm, Oliver, et al.
Publicado: (2009)

Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: A nationwide case‐control study
por: Ikeda, Sayaka, et al.
Publicado: (2020)

Harnessing the Potential of Plant Expression System towards the Production of Vaccines for the Prevention of Human Papillomavirus and Cervical Cancer
por: Shanmugaraj, Balamurugan, et al.
Publicado: (2022)

Lifetime risks, expected years of life lost, and cost-per-life year of esophageal cancer in Taiwan
por: Lai, Wu-Wei, et al.
Publicado: (2020)

Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
por: Toh, Zheng Quan, et al.
Publicado: (2019)

Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe
por: Chin’ombe, Nyasha, et al.
Publicado: (2014)

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
por: Kulasingam, Shalini L, et al.
Publicado: (2008)

From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness
por: Jit, Mark, et al.
Publicado: (2021)

Tuberculosis in Children and Adolescents, Taiwan, 1996–2003
por: Chan, Pei-Chun, et al.
Publicado: (2007)

Knowledge of Cervical Cancer Screening and Prevention by Human Papillomavirus Deoxyribonucleic Acid and Human Papillomavirus Vaccination among Women Attending a Tertiary Care Centre
por: Vaidya, Sapana Amatya, et al.
Publicado: (2023)

Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
por: Burger, E A, et al.
Publicado: (2012)

Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening
por: Huh, Warner K., et al.
Publicado: (2014)

Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland
por: Ginindza, Themba G., et al.
Publicado: (2017)

Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea
por: Lee, Hyunju, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8r5c225npleenle2kvfj5o1jj3